David Mahoney

DAVID MAHONEY is the Chief Executive Officer of iMcKesson, business unit
of McKesson HBOC, Inc. He also serves as co-CEO for McKesson HBOC, Inc.,
and is a member of the company’s Board of Directors. Mr. Mahoney brings
to his leadership role at iMcKesson an extensive background in the
healthcare industry as well as experience in strategy, acquisitions,
business-building and information technology-based operations. He joined
McKesson in 1990 as Vice President of Strategic Planning where he was
responsible for planning and corporate development. He is credited with
developing innovative business strategies to grow the PCS Health System
subsidiary, resulting in creation of significant shareholder value. Mr.
Mahoney played a key role in strategy development, identification and
negotiation of acquisitions and ultimately, the sale of PCS to Eli Lilly
& Company in 1994. Mr. Mahoney had overall responsibility for
McKessonHBOC’s strategic relations with pharmaceutical and biotechnology
companies, including managing the branded pharmaceuticals, generics, and
OTC/HBC purchasing and promotional programs for McKesson HBOC
Pharmaceutical Supply Management business. The Pharmaceutical Partners
Group of McKessonHBOC, which provides product development, sales and
marketing support to the pharmaceutical and biotechnology industry, was
built under Mr. Mahoney’s leadership. In addition, Mr. Mahoney has
overseen the development of several McKessonHBOC eHealth initiatives to
date. Prior to joining McKessonHBOC, he was a principal with McKinsey
&Company’s San Francisco office. At present, Mr. Mahoney is a director
of Nadro, the largest pharmaceutical distributor in Mexico. He was a
director of Cytel Corporation (now Epimmune), a biotechnology company,
from 1996-99 and was a director of Armor All Corporation from 1992-96.
Mr. Mahoney is a graduate of Harvard Business School and Princeton
University.